Aurinia Pharmaceuticals Inc (AUPH): Price and Financial Metrics
GET POWR RATINGS... FREE!
AUPH POWR Grades
- AUPH scores best on the Value dimension, with a Value rank ahead of 52.77% of US stocks.
- The strongest trend for AUPH is in Stability, which has been heading down over the past 31 weeks.
- AUPH's current lowest rank is in the Stability metric (where it is better than 3% of US stocks).
AUPH Stock Summary
- For AUPH, its debt to operating expenses ratio is greater than that reported by just 8.88% of US equities we're observing.
- With a price/sales ratio of 31.36, Aurinia Pharmaceuticals Inc has a higher such ratio than 92.69% of stocks in our set.
- Revenue growth over the past 12 months for Aurinia Pharmaceuticals Inc comes in at 15,938.36%, a number that bests 99.91% of the US stocks we're tracking.
- Stocks with similar financial metrics, market capitalization, and price volatility to Aurinia Pharmaceuticals Inc are RGLS, RVNC, OCX, SAGE, and TRVN.
- AUPH's SEC filings can be seen here. And to visit Aurinia Pharmaceuticals Inc's official web site, go to www.auriniapharma.com.
AUPH Stock Price Chart Interactive Chart >
AUPH Price/Volume Stats
|Current price||$12.86||52-week high||$20.50|
|Prev. close||$12.66||52-week low||$9.72|
|Day high||$12.89||Avg. volume||4,289,381|
|50-day MA||$12.59||Dividend yield||N/A|
|200-day MA||$14.03||Market Cap||1.65B|
Aurinia Pharmaceuticals Inc (AUPH) Company Bio
Aurinia Pharmaceuticals Inc., a clinical stage pharmaceutic] The company was formerly known as Isotechnika Pharma Inc. and changed its name to Aurinia Pharmaceuticals Inc. in October 2013. The company was founded in 1993 and is based in Victoria, Canada.
AUPH Latest News Stream
|Loading, please wait...|
AUPH Latest Social Stream
View Full AUPH Social Stream
Latest AUPH News From Around the Web
Below are the latest news stories about Aurinia Pharmaceuticals Inc that investors may wish to consider to help them evaluate AUPH as an investment opportunity.
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) ("Aurinia" or the "Company") is pleased to announce that the eight incumbent directors of the Company were elected at the Company’s annual general meeting (the "Meeting") held on June 7, 2021.
Aurinia Announces Additional Analysis of its AURORA 1 Phase 3 Study Data Presented at ERA-EDTA 2021 Congress
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (Aurinia or the Company) today presented an analysis of its Phase 3 AURORA 1 study data at the European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) 2021 Congress. The presentation follows the recent introduction of new data from an interim analysis of the AURORA 2 continuation study at the European Alliance of Associations for Rheumatology (EULAR) 2021 Congress.
Aurinia Pharmaceuticals (NASDAQ: AUPH ) shares experienced unusual options activity on Thursday. The stock price moved down to $13.6 following the option alert. Sentiment: BEARISH Option Type: TRADE Trade Type: CALL Expiration Date: 2021-07-16 Strike Price: $13.00 Volume: 350 Open Interest: 6105 Three Signs Of Unusual Options Activity One way options market activity can be considered unusual is when volume is exceptionally higher than its historical average. The volume of options activity refers to the number of contracts traded over a given time period. The number of contracts that have been traded, but not yet closed by either counterparty, is called open interest. A contract cannot be considered closed until there exists both a buyer and seller for it. Another indicator of unusual op...
Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) has announced a supportive interim analysis of its AURORA 2 continuation study evaluating Lupkynis (voclosporin) in lupus nephritis. Data will be presented at the upcoming European Alliance of Associations for Rheumatology (EULAR) 2021 Congress in June. Subjects who completed one year of treatment in Aurinia's Phase 3 AURORA 1 study were eligible to enroll in the continuation study (AURORA 2). The interim analysis of AURORA 2 showed that subjects in the Lupkynis treatment arm sustained meaningful reductions in proteinuria, with no change in mean estimated glomerular filtration rate (eGFR) at 104 weeks of treatment. Proteinuria continued to improve with a greater reduction in UPCR from pre-treatment baseline to year two observed in the voclospor...
Aurinia To Present Supportive AURORA 2 Continuation Study Interim Analysis Demonstrating Long-Term Safety & Efficacy of LUPKYNIS™ (voclosporin) in Subjects with Lupus Nephritis
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (Aurinia or the Company) announced today that a supportive interim analysis of its AURORA 2 continuation study will be presented at the upcoming European Alliance of Associations for Rheumatology (EULAR) 2021 Congress June 2-5, 2021.
AUPH Price Returns
Continue Researching AUPHHere are a few links from around the web to help you further your research on Aurinia Pharmaceuticals Inc's stock as an investment opportunity:
Aurinia Pharmaceuticals Inc (AUPH) Stock Price | Nasdaq
Aurinia Pharmaceuticals Inc (AUPH) Stock Quote, History and News - Yahoo Finance
Aurinia Pharmaceuticals Inc (AUPH) Stock Price and Basic Information | MarketWatch